0102030405
Tirzepatide Dual GLP-1 da GIP Mai karɓar Agonist don Gudanar da nauyi da Kula da Glycemic
Cikakken Bayani
Tirzepatide wani sabon magani ne da ake amfani da shi don kula da nauyi na dogon lokaci a cikin marasa lafiya masu kiba masu kiba ko kuma cututtukan da ke da alaƙa da nauyi. Yana da agonist mai dogaro da glucose na glucagon polypeptide (GIP) da glucagon-kamar peptide-1 (GLP-1). FDA ta amince da ita a cikin 2022, tirzepatide ya haɗu da tasirin proinsulin na ciki guda biyu a cikin kwaya ɗaya, yana haɓaka haɓakar insulin da rage matakan glucagon. Wannan labarin yana bincika tsarin aikin, ingancin asibiti, da bayanin martaba na tirzepatide a matsayin magani mai mahimmanci don asarar nauyi da ingantaccen sarrafa glycemic a cikin marasa lafiya da nau'in ciwon sukari na 2.
I. Fahimtar Tirzepatide:
A. Glucose-dogara agonist na GIP da GLP-1 masu karɓa
B. Tsarin aiki: haɓaka lokaci na I da na II siginar insulin, rage matakan glucagon
II. Amfanin asibiti da Amincewar FDA:
A. Nuni: Gudanar da nauyin nauyi na dogon lokaci a cikin marasa lafiya masu kiba tare da manyan kiba ko abubuwan da ke da alaƙa da nauyi
B. Maganin haɗin gwiwa don inganta sarrafa glycemic a cikin manya da nau'in ciwon sukari na 2
C. Amincewar FDA da talla ta Eli Lilly a cikin 2022
III. Inganci a Gudanar da Nauyi:
A. Kwatankwacin tasiri:
Kashi na asarar nauyi: Low-dose (5mg), matsakaici-kashi (10mg), da babban kashi (15mg) kungiyoyin
Matsakaicin asarar nauyi a cikin ƙungiyoyin sashi daban-daban
Kwatanta da rukunin placebo
Kashi na batutuwan da ke samun asarar nauyi sama da 20%
B. Bayanin Tsaro: Mitar halayen mara kyau idan aka kwatanta da rukunin placebo
C. Kwatanta da sauran magungunan rage nauyi:
Orlistat (over-the-counter): Bambanci a cikin adadin asarar nauyi
IV. Hanyar sarrafa Glycemic da Rage nauyi:
A. Kunna GLP-1 da GIP masu karɓa
B. Ciki da rage cin abinci
Tirzepatide, a matsayin dual GLP-1 da GIP agonist mai karɓa, yana ba da ingantaccen kulawar nauyi da ingantaccen sarrafa glycemic a cikin marasa lafiya masu kiba da kiba mai girma ko cututtukan da ke da alaƙa da nauyi, da kuma a cikin mutane masu ciwon sukari na 2. Tsarin aikinta na dogaro da glucose yana haɓaka haɓakar insulin kuma yana rage matakan glucagon. Tare da babban adadin asarar nauyi da ingantaccen bayanin martaba, tirzepatide ya fito waje a matsayin magani mai ƙarfi don sarrafa nauyi na dogon lokaci. Ƙarin bincike da nazarin asibiti za su ci gaba da gano abubuwan da za a iya amfani da su da kuma aikace-aikacen wannan magani mai ban sha'awa.
Domin samar da ingantacciyar ƙwarewar ciniki, za mu iya siffanta capsule da samfuran ruwa, gwargwadon buƙatun abubuwan sinadaran ku.
Za mu iya siffanta sashi: 500mg/capsule, 550mg/capsule, 600mg/capsule.
Za mu iya siffanta marufi: 60 iyakoki / kwalban, 90 iyakoki / kwalban, 120 iyakoki / kwalban.
Za mu iya siffanta capsule bawo da launuka: shuka capsule bawo, gelatin capsule bawo.
Ƙayyadaddun bayanai
